Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery
Open Access
- 19 February 2024
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 379 (1899) , 20220381
Abstract
Impairment of autophagic–lysosomal pathways is increasingly being implicated in Parkinson's disease (PD). GBA1 mutations cause the lysosomal storage disorder Gaucher disease (GD) and are the commonest known genetic risk factor for PD. GBA1 mutations have been shown to cause autophagic–lysosomal impairment. Defective autophagic degradation of unwanted cellular constituents is associated with several pathologies, including loss of normal protein homeostasis, particularly of α-synuclein, and innate immune dysfunction. The latter is observed both peripherally and centrally in PD and GD. Here, we will discuss the mechanistic links between autophagy and immune dysregulation, and the possible role of these pathologies in communication between the gut and brain in these disorders. Recent work in a fly model of neuronopathic GD (nGD) revealed intestinal autophagic defects leading to gastrointestinal dysfunction and immune activation. Rapamycin treatment partially reversed the autophagic block and reduced immune activity, in association with increased survival and improved locomotor performance. Alterations in the gut microbiome are a critical driver of neuroinflammation, and studies have revealed that eradication of the microbiome in nGD fly and mouse models of PD ameliorate brain inflammation. Following these observations, lysosomal–autophagic pathways, innate immune signalling and microbiome dysbiosis are discussed as potential therapeutic targets in PD and GD. This article is part of a discussion meeting issue ‘Understanding the endo-lysosomal network in neurodegeneration’.Keywords
Funding Information
- Wellcome Trust (214589/Z/18/Z)
- Rosetrees Trust (M701)
This publication has 196 references indexed in Scilit:
- Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated AutophagyScience, 2004
- Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of MicrogliaThe Journal of Neuroscience, 2001
- The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic SystemNeurobiology of Disease, 2000
- Cytokines in Gaucher's disease.1999
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998
- Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10QJM: An International Journal of Medicine, 1997
- Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's diseaseNeuroscience Letters, 1996
- Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patientsNeuroscience Letters, 1994
- Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patientsNeuroscience Letters, 1994
- Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brainsNeurology, 1988